Halberd Receives Patent for Treatment of Cockayne Syndrome — May Provide Pathway to Slow Aging

Jackson Center, PA – Halberd Corporation (OTC-PINK: “HALB“) received notification from the Ference Law Firm in Pittsburgh of a Notice of Allowance, by the US Patent Office, for the treatment of Cockayne Syndrome.

Cockayne Syndrome is a fatal autosomal recessive neurodegenerative disorder which causes premature aging and severely impaired development of the nervous system.  Cockayne Syndrome is one of only a few known diseases which cause premature aging.  Halberd’s scientific team and patent counsel believe that this is one of the first granted patents which could slow the aging process.  This intellectual property also greatly strengthens the existing intellectual property of Halberd.  This patent application utilizes Halberd’s patented extra-corporeal methodology for the development of treatments for infectious diseases, such as PTSD, CTE, Alzheimer’s Disease, and others.

Mitchell S. Felder, M.D., Halberd’s Chief Technology Officer, and board certified neurologist, stated, “From time immemorial, mankind has dreamed of finding a method for slowing the aging process.  I believe that this granted patent may be a first step in achieving that dream.  It may also potentially open the door for the treatment of a great many other neurodegenerative maladies (Alzheimer’s Disease, Parkinson’s Disease, PTSD, CTE, etc.).  In part, this granted patent teaches a technique for precisely controlling the exact pico-gram/ml concentration of Death-Associated Protein 1 (DAP1).  Obviously, less DAP1 may lead to reduced premature death(s).”

William A. Hartman, Chairman, President & CEO added, “The potential to slow the aging process presents phenomenal possibilities!  The beautiful part of Halberd’s technology is that all of our work on different major diseases involves the same fundamental elements–extracorporeal (outside the body) application, antibodies, antigens, the same university partners, Chemical Bonding, Lasers, and Radio Frequency elimination techniques.  This commonality allows us to pursue a wide variety of major diseases by altering only our created antibodies and the target antigens. That makes Halberd equivalent of a huge biomedical corporation with a massive collection of patented intellectual property covering multiple major diseases.  This makes Halberd’s technology similar to a screwdriver with interchangeable tips – it uses the same basic tool.”

Hartman continued, “This Cockayne Syndrome/ Aging patent could be the first step in the discovery of an actual “Fountain of Youth”. Halberd’s strategy has been to pursue those diseases that are: 1) Major; 2) Have no known effective cures; 3) Are within our capability to deliver in the short term utilizing our existing technology, and 4) Covered by our strong patent protection.  We are working to revolutionize medicine, not just to find another treatment!

Equally important – we are building the foundation of common thread of strategies with profound prospects for universal application, addressing numerous medical maladies.”

About Halberd Corporation
Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.  It holds the exclusive worldwide rights to numerous patent- and PCT-pending extracorporeal treatments for COVID-19 and other medical maladies:  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

To get the latest news on Halberd’s exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)

William A. Hartman
[email protected];
[email protected]

Halberd Corporation